What it is
TB-500 is a synthetic peptide related to a region of the naturally occurring protein thymosin beta-4. It is supplied as a research chemical, not as a registered medicine.
The Range
TB5 · Pen · Tissue & cytoskeletal research
TB-500 5 mg pen
Research-onlyEvidence: Preclinical
A synthetic fragment related to thymosin beta-4. Studied in preclinical models for its role in cell migration and tissue remodelling processes.
Information only
TB-500 is presented as reference information for registered healthcare professionals. Availability is subject to applicable law, prescription or Section 21 authorisation, and licensed pharmacy channels. No dosing, protocol or self-administration guidance is given, and nothing here is an offer of sale.
Evidence highlights
Mechanism being studied
Laboratory research has examined actin-binding activity and effects on cell migration, which are relevant to wound-repair biology. Translation of these observations to clinical outcomes has not been established.
Human evidence
Human clinical evidence is minimal. Related thymosin beta-4 formulations have been investigated in early-phase studies, but TB-500 itself lacks adequate controlled trials in people.
Evidence & Regulation
Where the evidence for TB-500 sits, and the rules that apply to it
Every source below is a public, primary source — a literature index, a trials registry, or a regulator. They are reading directions for professionals, not endorsements, and they do not establish that any use of TB-500 is approved, safe or appropriate.
Citations
- Peer-reviewed literature — PubMed search: "thymosin beta 4 TB-500"
LiteratureIndependent index of published studies. Most entries for research peptides are preclinical.
- SAHPRA — South African Health Products Regulatory Authority
RegulatorThe South African regulator. Health products must be registered or authorised before they may lawfully be sold here.
- WADA Prohibited List
SportNon-approved substances (class S0) and growth-factor classes are prohibited in sport at all times.
Further reading
- Peer-reviewed thymosin beta-4 literature indexed in PubMed.
- World Anti-Doping Agency Prohibited List.
- SAHPRA — guidance on unregistered health products.
How the regulation works
Registration comes before supply
In South Africa, a product intended to treat, prevent or otherwise affect the functioning of the body is a medicine and must be registered with SAHPRA before it may lawfully be sold. An unregistered compound cannot be advertised or supplied to the public, regardless of the evidence behind it.
SAHPRA — medicines registrationSection 21 is the professional access route
Where no registered alternative exists, a registered healthcare professional may apply to SAHPRA under Section 21 for authorisation to access an unregistered product for a named patient. That application is made by the clinician, not by the patient, and not by us.
Section 21 pathwayPrescription and dispensing stay with licensed channels
Any prescribing decision, dosing decision and dispensing step belongs to a registered healthcare professional and a licensed pharmacy. We publish reference information and analytical documentation only, and never dosing, protocols or self-administration guidance.
Prohibited in sport
Non-approved substances are prohibited at all times under the World Anti-Doping Code, including many research peptides. Athletes under testing jurisdiction should treat every compound on this site as prohibited unless their governing body confirms otherwise.
WADA Prohibited ListStatus is jurisdiction-specific
A compound may be an approved medicine in one country, an investigational agent in a second, and an unregistered research chemical in a third. Always confirm the classification that applies where you practise before acting on any information here.
EMA medicines databaseInformation only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.